当前位置: X-MOL 学术Lancet HIV › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Antiretroviral resistance and management after pre-exposure to prophylaxis.
The Lancet HIV ( IF 12.8 ) Pub Date : 2020-02-01 , DOI: 10.1016/s2352-3018(19)30404-7
Victoria Tittle 1 , Marta Boffito 2 , Alan McOwan 1 , Gary Whitlock 1 ,
Affiliation  

HIV pre-treatment genotypic resistance has been reported in less than 0·1% of users of pre-exposure prophylaxis (PrEP) because of the effectiveness of PrEP in preventing HIV transmission. However, in the subgroup of PrEP users that do acquire HIV, genotypic resistance in 20 (29%) of 68 patients has been documented, and data on how to manage this group are in short supply. In this Correspondence, we present real-life, baseline resistance data comparing previous users of PrEP (tenofovir disoproxil fumarate and emtricitabine) and non-PrEP users, which were obtained from patients with newly diagnosed HIV at a sexual health and HIV clinic in central London, UK. We also describe the management and outcomes of these patients.

中文翻译:

预暴露于预防后的抗逆转录病毒耐药性和管理。

据报道,由于 PrEP 在预防 HIV 传播方面的有效性,暴露前预防 (PrEP) 使用者中不到 0·1% 的用户报告了 HIV 治疗前基因型耐药。然而,在确实感染 HIV 的 PrEP 使用者亚组中,68 名患者中有 20 名(29%)的基因型耐药已被记录,并且关于如何管理该组的数据短缺。在本通讯中,我们提供了现实生活中的基线耐药数据,比较了之前使用 PrEP(富马酸替诺福韦酯和恩曲他滨)和非 PrEP 用户的数据,这些数据来自伦敦市中心一家性健康和 HIV 诊所的新诊断 HIV 患者, 英国。我们还描述了这些患者的管理和结果。
更新日期:2020-02-04
down
wechat
bug